Medical Research
(H112)
IRS Verified
DX Registered
990 on File
TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION
Financial strength (30%)
94/100
Reliability (20%)
55/100
Effectiveness (25%)
83/100
Impact (25%)
No data yet
Register and add impact metrics to be rated above three stars
CharityAI™ Score
Not yet evaluated
Mission Statement
TGen's Center for Rare Childhood Disorders (C4RCD) applies the latest tools of genomic medicine to provide answers for parents seeking to identify the disease or disorder affecting their child. We harness the latest technologic leaps in genome sequencing to pinpoint the causes of rare childhood disorders that largely remain a mystery to modern medicine. Ours is a four-pronged effort, consisting of: Clinical evaluation and genomic diagnosis Optimizing conventional therapy Novel therapy development Community outreach
Financial Overview — FY 2025
$11.6M
Total Revenue
$8.7M
Total Expenses
$15.0M
Net Assets
0
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
83.7%
Fundraising Efficiency
N/A
Operating Reserve
20.74x
Liability-to-Asset
29.3%
Revenue Diversification
92.7%
Executive Compensation
$363K
Compared with Peers
FY 2025
Compared with 162 similar organizations
(United States, Medical Research, $1M–$10M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
83.7% | 83.4% |
P10P90
|
Above median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
1.7% | 10.4% |
P10P90
|
Top quarter |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
14.7% | 2.9% |
P10P90
|
Bottom quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
20.7 mo | 13.3 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
29.3% | 13.2% |
P10P90
|
Bottom quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
92.7% | 90.6% |
P10P90
|
Below median |
|
Revenue growth
Year over year revenue growth
|
5.0% | 7.8% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
-25.2% | 3.2% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
25.1% | 4.6% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $11.6M | $8.7M | $15.0M | 83.7% | 0 |
| 2024 | $11.0M | $11.6M | $12.1M | 83.6% | 0 |
| 2023 | $15.4M | $17.0M | $12.6M | 87.6% | 0 |
| 2022 | $11.6M | $13.1M | $14.2M | 84.6% | 0 |
| 2021 | $3.8M | $14.2M | N/A | — | 0 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.